Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
100.57
132.77
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC
Accounts Receivables
Jazz Pharmaceuticals PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Accounts Receivables
$723.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Accounts Receivables
$813.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Accounts Receivables
$37.1m
|
CAGR 3-Years
412%
|
CAGR 5-Years
32%
|
CAGR 10-Years
29%
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Accounts Receivables
€23.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
18%
|
CAGR 10-Years
3%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Accounts Receivables
€175k
|
CAGR 3-Years
25%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
Jazz Pharmaceuticals PLC
Glance View
In the bustling world of global pharmaceuticals, Jazz Pharmaceuticals PLC has carved out a niche for itself through its focus on specialty pharmaceuticals addressing unmet medical needs. Founded in 2003, Jazz has grown significantly by acquiring and developing unique products that serve smaller patient populations but address significant health challenges. Its journey is one of careful strategy and thoughtful innovation. The company first gained attention with its sleep disorder portfolio, most notably Xyrem, a treatment for narcolepsy that quickly became a cornerstone of its revenue stream. Jazz's adeptness at navigating complex regulatory and market environments has played a crucial role in its success, allowing it to maintain a stronghold in niche therapeutic markets. Building on its initial successes, Jazz began to diversify its portfolio, expanding into oncology and neuroscience. The acquisition of companies like Celator Pharmaceuticals and GW Pharmaceuticals was a strategic move to broaden its research capabilities and tap into the lucrative, yet challenging, segments of cancer and cannabinoid therapies. Jazz’s pipeline is rich with promising candidates, reflecting its commitment to long-term growth through innovation. Central to its business model is the commercialization of these specialized, high-value drugs, which are marketed to healthcare providers and directly impact patient outcomes. By focusing on diseases with few effective treatments, Jazz positions itself as a leader in transforming lives, all while sustaining its financial health through carefully managed margins and a global reach in its distribution and research efforts.
See Also
What is Jazz Pharmaceuticals PLC's Accounts Receivables?
Accounts Receivables
723.6m
USD
Based on the financial report for Sep 30, 2024, Jazz Pharmaceuticals PLC's Accounts Receivables amounts to 723.6m USD.
What is Jazz Pharmaceuticals PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
14%
Over the last year, the Accounts Receivables growth was 15%. The average annual Accounts Receivables growth rates for Jazz Pharmaceuticals PLC have been 13% over the past three years , 22% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet